Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company, will have its CEO, Richard Peters, present at the H.C. Wainwright BioConnect Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7 a.m. EST through the conference portal and Yumanity's website. The company is focused on developing therapies for neurodegenerative diseases, with its leading candidate, YTX-7739, in clinical trials for Parkinson’s disease.

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference, being held virtually January 10-13, 2022.

The presentation will be available on-demand via the conference portal and through the Company's website at www.yumanity.com/events beginning at 7 a.m. EST, January 10.

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is in clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com.

Investors:
Burns McClellan, Inc.
Lee Roth
lroth@burnsmc.com
(212) 213-0006

Media:
Burns McClellan, Inc.
Robert Flamm, Ph.D.
rflamm@burnsmc.com
(212) 213-0006

FAQ

When will Yumanity Therapeutics present at the H.C. Wainwright BioConnect Conference?

Yumanity Therapeutics will present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022.

What is the focus of Yumanity Therapeutics' drug development?

Yumanity Therapeutics focuses on developing innovative therapies for neurodegenerative diseases.

What is Yumanity's leading product candidate?

Yumanity's leading product candidate is YTX-7739, which is in clinical development for Parkinson’s disease.

Where can I access the presentation from Yumanity Therapeutics?

The presentation will be available on-demand starting January 10 at 7 a.m. EST on Yumanity's website and the conference portal.

What diseases does Yumanity Therapeutics target?

Yumanity Therapeutics targets various neurodegenerative diseases, including Lewy body dementia, ALS, and Alzheimer's disease.